U.S. Markets close in 4 hrs 1 min

AlloSure for Heart Transplant Patients Receives CMS Draft Coverage

CareDx expands leadership with cfDNA for transplant care

BRISBANE, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces AlloSure received a positive draft Local Coverage Determination (dLCD) for Medicare coverage in heart transplant patients.

The Centers for Medicare and Medicaid Services (CMS) released the draft version of the coverage policy issued by Palmetto GBA, the Medicare administrator responsible for the MolDX technology assessment program that evaluated AlloSure. Forty percent of heart transplant patients are covered by Medicare.

“AlloSure provides additional insights into antibody mediated rejection in heart transplant patients, an indication that is growing in our patient population,” said Dr. Jonathan Kobashigawa, Medical Director at Cedars Sinai. “When paired with AlloMap, we have a strong tool for patient surveillance through the life of their allograft.”

“We have some strong early experience with HeartCare where clinicians are seeing the value of AlloSure and AlloMap in patient management,” said Peter Maag, CEO of CareDx.  “MolDX’s draft coverage underscores the value we bring to transplant patient care.” 

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements, including statements regarding AlloSure Heart. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com 

Investor Relations
David Clair
Westwicke Partners
646-277-1266
david.clair@icrinc.com